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SObjective: The objective of this study was to evaluate long-term survival and prognostic factors in patients with
malignant pleural mesothelioma.
Methods: All consecutive patients referred for surgical diagnosis and/or pleurodesis for malignant pleural
mesothelioma between 2000 and 2010 were studied. The following parameters were prospectively recorded:
age, sex, tobacco consumption, asbestos exposure, type and duration of symptoms, American Society of Anes-
thesiologists (ASA) score, body mass index, preoperative C-reactive protein levels, white blood cells and plate-
let count, pachypleuritis on chest radiograph, type of diagnostic surgical procedure, histologic type, modality of
pleurodesis, and chemotherapy. Survival was assessed on March 1, 2011.
Results: A total of 170 patients were included. For the entire population, median survival was 12 months
(95% confidence interval [CI], 10-15). Two-, 5-, and 7-year overall survival was 26% (95% CI, 19-35),
11% (95% CI, 6-21), and 5% (95% CI, 9-22), respectively. Asbestos exposure, age, ASA class III versus
ASA classes I and II, nonepithelioid histology, C-reactive protein levels>3 mg/L, and white cell count
>12,000/mm3 influenced outcome in univariate analysis. Multivariate analysis showed that nonepithelioid
histology (hazard ratio [HR], 2.76; 95% CI, 1.50-5.08); age (HR, 1.05; 95% CI, 1.01-1.08); C-reactive pro-
tein levels between 4 and 50 mg/L, and>51 (HR, 2.28; 95% CI, 1.18-4.42; and HR, 2.69; CI, 1.29-5.60,
respectively); and leukocytosis>12,000/mm3 (HR, 2.28; 95% CI, 1.22-4.25) were independent worse sur-
vival predictors.
Conclusions: Median survival in an unselected population of patients with malignant pleural mesothelioma
treated nonsurgically is 12 months. Nonepithelioid histology, older age, abnormal C-reactive protein levels,
and leukocytosis are independent predictors of worse survival. (J Thorac Cardiovasc Surg 2013;145:1305-11)Malignant pleural mesothelioma (MPM) remains a public
health issue, although asbestos use was discontinued ap-
proximately 2 decades ago in most countries, the incidence
of the disease is currently stable.1-3 Furthermore, several
working categories are still exposed to asbestos during
maintenance or renovation work because of the lack of
constant application of protection measures.4 Diagnosis is
often late because symptoms are rather unspecific, particu-
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The Journal of Thoracic and Carfor the diagnosis but is often difficult, requiring large tissues
samples to allow assessment of fat or intercostal muscle in-
vasion by the mesothelial proliferation as well as immuno-
histochemical staining.6,7 Therefore, a surgical biopsy is
frequently required.6,7
Despite chemotherapy progresses—particularly with the
use of new antimetabolites pemetrexed8 and ralitrexed9—
the impact on survival is moderate. Large-scale studies of
a multimodality therapy based on association of chemother-
apy and aggressive surgery (extrapleural pneumonectomy)
showed disappointing results, with a 5-year survival of ap-
proximately 15%.10-12 Nevertheless, our knowledge on
long-term outcome comes from few therapeutic studies
and registries; therefore, prognostic factors are heteroge-
neous and often discordant among these different re-
ports.13-16 This study aimed at assessing survival and its
determinants in a series of unselected patients with MPM.METHODS
Clinical and pathologic data of all patients referred to the thoracic sur-
gery department of Ho^tel-Dieu Hospital, Paris, France, between November
1, 2000, and October 31, 2010, for video-assisted or open pleural biopsy
and/or pleurodesis for MPM were collected prospectively and reviewed
retrospectively. Patients undergoing surgery in a curative intent bydiovascular Surgery c Volume 145, Number 5 1305
TABLE 1. Patient characteristics
Variable n (%) or mean ± SD
Demographics and risk factors
FIGURE 1. Flow diagram of patients. MPM, Malignant pleural
mesothelioma.
Abbreviations and Acronyms
CI ¼ confidence interval
CRP ¼ C-reactive protein
IL ¼ interleukin
MPM ¼ malignant pleural mesothelioma
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tion is not performed at our institution. For all patients, pathologic diagno-
sis was performed by board-certified pathologists highly specialized in
thoracic pathology. All cases were also reviewed by the French national
MPM panel (Mesopath Group).
The following parameters were recorded: age, sex, tobacco consump-
tion, asbestos exposure, type and duration of symptoms (cough, dyspnea,
pain, weight loss), American Society of Anesthesiologists score, body
mass index, preoperative C-reactive protein (CRP) levels, white blood cells
and platelet count, presence of pachypleuritis on chest radiograph, type of
diagnostic surgical procedure (open vs video assisted), and histologic type.
C-reactive protein levels were measured by nephelometry as part of the
routine preoperative workup. The lower limit of detection was 3 mg/L,
which was chosen as the cutoff. Based on empirical clinical relevance,
a second cutoff was set at 50 mg/L.
Data on long-term outcomewere obtained by direct phone interviews of
patients, family (in case of deceased patients), and referring physicians.
When no clinical follow-up was available (deceased patients, impossibility
of contacting family, retired referring physicians), information on vital sta-
tus perMarch 1, 2011, was obtained through the municipality of birth of the
patient.
Informed consent was obtained from patients or relatives (in the case of
deceased patients). The research was conducted according to recommenda-
tions outlined in the Helsinki Declaration. Institutional review board ap-
proval was obtained.Gender, men 121 (71)
Age, years 72.7  9.6
Identified asbestos exposure 73 (46)
History of previous malignancy 25 (15)
Smokers or ex-smokers 81 (48)
Initial presentation
Dyspnea, chest pain, cough 125 (75), 57 (34), 34 (20)
Weight loss 40 (25)
Right-sided, left-sided, bilateral
localization
105 (64), 58 (35), 2 (1)
Biology
CRP, median 22.5 (Q1, 6; Q3, 75)
CRP 3 mg/L 28 (18)
CRP>3 mg/L 130 (82)
CRP ¼ 3-50 mg/L 79 (50)
CRP>50 mg/L 51 (32)
Blood leukocytes count/mm3 8907  2658
Platelets count/mm3 354,800  129,486
Surgery
ASA I, II, III 5 (4), 92 (65), 44 (31)
Video-assisted surgery 157 (92.3)
Talc pleurodesis 125 (76)
MPM
Epithelioid 135 (81)
Biphasic, sarcomatoid, desmoplastic 17 (10), 9 (5), 5 (3)
SD, Standard deviation; CRP, C-reactive protein; Q, quartile; ASA, American Society
of Anesthesiologists; MPM, malignant pleural mesothelioma.Patient Management
All patients underwent thoracic and upper abdominal computed tomo-
graphic scan. Surgery was carried out under general anesthesia, using
a 2-port technique in case of video-assisted thoracoscopy. Decision of per-
forming talc pleurodesis was based on clinical and radiologic data, and on
the perioperative aspect of the pleura and results of frozen sections analysis.
Our surgical institution is a tertiary referral center, with most
patients addressed by several physicians and different hospitals. After
discharge, patients were managed by referring physicians. Thus, indi-
cations for chemotherapy and timing with respect to interventions
were largely variable. Chemotherapy proposition was discussed indi-
vidually following multidisciplinary evidence-based meetings. Al-
though no uniform protocol was applied, associations of platinum
salts (gemcitabine) and of platinum salts (pemetrexed) were used
primarily before and after 2005, respectively.
Data Analysis
Data processing and analysis were performed with R version 2.15.1,
a language and environment for statistical computing (R Foundation for
Statistical Computing, Vienna, Austria). Results are expressed as percent-
age, mean standard deviation for normally distributed, and median (first
quartile, third quartile) for non-normally distributed, quantitative variables.
Survival analysis was carried out using the Kaplan-Meier method, and uni-
variate comparisons of curves were performed using log-rank tests. Crude
hazard ratios were also estimated using univariate Coxmodels. All the vari-
ables associated significantly with survival in univariate analysis were en-
tered into a multivariate Cox model to identify independent predictors of
survival. A P value< .05 was considered significant.1306 The Journal of Thoracic and Cardiovascular SurRESULTS
Patients Characteristics
Of 202 surgical procedures in patients with MPM,
32 had a curative intent. The remaining 170 patientsgery c May 2013
FIGURE 2. A, Kaplan-Meier overall survival of the whole population. B, Kaplan-Meier overall survival with respect to gender. C, Kaplan-Meier overall
survival with respect to asbestos exposure. D, Kaplan-Meier overall survival with respect to American Society of Anesthesiologists (ASA) class.
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followed by a nonsurgical treatment, and were included
in the study (Figure 1). Table 1 shows the main charac-
teristics of patients, surgical procedures, and MPM
type.
Thirteen patients (7.7%) had a diagnostic minithoracot-
omy because of pachypleuritis without evident effusion.
At thoracoscopy, only 10 patients (5.9%) had a simple as-
pect of pleural inflammation, whereas for the remaining pa-
tients, nodules or pleural thickness were evident (65.9%
and 64.7% of patients, respectively) and often associated.
Only 2 patients had a disease limited to the parietal pleura,
whereas the remaining had parietal pleura involvement as-
sociated with visceral, mediastinal, or diaphragmatic pleu-
ral disease.
In a minority of patients, talc pleurodesis was not
performed because of either pachypleuritis with no effusion
(n ¼ 13, 7.6%) or lack of sufficient intraoperative data
(atypical presentation, thoracoscopic aspect, inconclusive
histologic frozen sections) to justify talc pleurodesis. For
these patients, instillation of povidone iodine was carried
out. Postoperative mortality was 0.6% (n ¼ 1).
Postoperative treatment included chemotherapy associ-
ated with supportive care in 105 patients (61.8%), and
supportive care alone in the remaining patients.The Journal of Thoracic and CarLong-Term Survival
Information regarding survival was available for 159 pa-
tients (94%). For 4 of 159 patients, information could be
obtained only by interrogation of municipalities registries
(because of deceased patients, families that couldn’t be
reached, and retired referring physicians). On completion
of the study (March 2011), 40 of these patients were alive
and 119 were dead. Median survival was 12 months (95%
confidence interval [CI], 10-15); a 2-, 5-, and 7-year overall
survival was 26% (95% CI, 19-35), 11% (95% CI, 6-21),
and 5% (95% CI, 9-22), respectively (Figure 2). Character-
istics of long term survivors (5 years) are detailed in
Table 2.Predictors of Survival
Table 3 shows the factors that were associated signifi-
cantly with survival in univariate analysis. Age was associ-
ated with survival (P ¼ .008) and men had a worse
prognosis (P ¼ .03, Figure 2). Weight loss was not associ-
ated significantly with survival, whereas asbestos exposure
and American Society of Anesthesiologists class was
(P ¼ .002 and P ¼ .007, respectively; Figure 2). With re-
spect to surgical and pathological data, non-epithelioid his-
tology negatively affected outcome (P ¼ .005) (Figure 3)diovascular Surgery c Volume 145, Number 5 1307
TABLE 2. Characteristics of patients with survival 5 years (n ¼ 4)
Variable n (%) or median (Q1, Q3)
Demographics and risk factors
Gender, men 2 (50%)
Age, years 61 (54, 66)
Identified asbestos exposure 2 (50)
History of previous malignancy 1 (25)
Smokers or ex-smokers 1 (25)
Initial presentation
Dyspnea, chest pain, cough 3 (75), 1 (25), 0 (0)
Weight loss 0 (0)
Right-sided, left-sided, bilateral
localization
0 (0), 2 (50), 2 (50)
Biology
CRP 3 (3, 16)
CRP>3 mg/L 1 (25) (value 56)
Blood leukocytes count 7600 (6575, 9425)
(1>12,000 value 12,500)
Platelets count 368,000 (316,200, 427,200)
Surgery
ASA I, II, III 0 (0), 4 (100), 0 (0)
Talc pleurodesis 3 (75)
MPM
Epithelioid 4 (100)
Q, Quartile; CRP, C-reactive protein; ASA, American Society of Anesthesiologists;
MPM, malignant pleural mesothelioma.
TABLE 3. Factors associated with survival in univariate analysis
Variable
Crude hazard
ratios (95% CI) P value
Age, years 1.03 (1.007-1.048) .008
Gender
Men 1.57 (1.03-2.37) .03
Women 1
Identified asbestos exposure
Yes 1.54 (1.05-2.24) .02
No 1
ASA
III 1.86 (1.17-2.94) .007
I-II 1
Histologic type
Nonepithelioid 1.90 (1.20-2.99) .005
Epithelioid 1
CRP
>3 mg/L 1.97 (1.16-3.36) .01
3 mg/L 1
CRP
>50 mg/L 2.47 (1.37-4.46) .003
3-50 mg/L 1.74 (0.99-3.04) .05
3 mg/L 1
White cell count
>12,000/mm3 1.75 (1.05-2.92) .03
12,000/mm3 1
CI, Confidence interval; ASA, American Society of Anesthesiologists; CRP, C-
reactive protein.
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(P ¼ .16). CRP levels  3 mg/L, between 4 and 50 and
>51 mg/L were associated with survival (P ¼ .008,
Figure 3). Leukocytosis (>12,000/mm3) negatively affected
outcome (P¼ .03) (Figure 3), whereas an increased platelet
count (>400,000/mm3) did not influence survival (P¼ .95).
Multivariate analysis showed that MPM histological
type, age, CRP levels, and leukocytosis were independent
predictors of worse survival (Table 4).DISCUSSION
This large cohort study confirmed the poor survival of pa-
tients with MPM and identified independent prognostic fac-
tors including histologic type, age, and markers of systemic
inflammation (ie, CRP levels and leukocyte count). The
main limitations of our study are represented by the retro-
spective character of the study (precluding the exact assess-
ment of cause of death and imposing the assessment of
overall survival rather than disease-specific survival) and
by the heterogeneity in postsurgical care, especially chemo-
therapy, preventing the possibility of rigorous survival anal-
ysis with respect to its administration. However, its main
strengths are the large number of consecutive patients re-
ferred to a single surgical center who had exhaustive clinical
and laboratory assessment as well as the long follow-up.
Knowledge of long-term outcome of patients with MPM
is derived from a few registry studies, some retrospective
observational studies, and a limited number of therapeutic1308 The Journal of Thoracic and Cardiovascular Surtrials.8-16 Studies of registries have been reviewed
recently by Montanaro and colleagues16: median survival
times ranged from 5.0 to 13.2 months and 1-year survival
rates from 29% to 46%. Only 2 of 13 registry studies re-
ported 5-year survival rates, which were 5% in both cases.16
Therapeutic trials have reported variable results and, in
all cases, included a very selected subset of patients. In
a phase III study comparing the association of pemetrexed
and cisplatin with cisplatin alone, 456 patients were eval-
uated. Median survival time in the pemetrexed–cisplatin
arm was 12.1 months versus 9.3 months in the cisplatin
arm,8 providing the basis of current recommendations
for MPM chemotherapy. Although chemotherapy is often
the sole treatment administered to patients with MPM,
multimodality treatment, including radiation therapy,
extensive surgery, and chemotherapy, is an option for se-
lected patients with limited disease extension. However,
following initial enthusiasm,17 more recent studies have
shown that extrapleural pneumonectomy in the setting of
a multimodality treatment is associated with a 25% to 42%
2-year survival rate.10-12,18 Two studies in 70 patients and
73 patients, showed 5-year survival rates of 15% and 10%,
respectively, raising the question of the real benefit of exten-
sive surgery.11,12 Results of the randomized Mesothelioma
and Radical Surgery trial do not seem to favor the
association chemotherapy–extrapleural pneumonectomygery c May 2013
FIGURE 3. A, Kaplan-Meier overall survival with respect to histologic type. B, Kaplan-Meier overall survival with respect to blood leukocyte count.
C and D, Kaplan-Meier overall survival with respect to C-reactive protein (CRP) levels.WBC, White blood cells.
TABLE 4. Factors associated independently with survival in
multivariate analysis
Variable
Adjusted hazard
ratios (95% CI) P value
Nonepithelioid histologic type 2.76 (1.50-5.08) .001
Age, years 1.05 (1.01-1.08) .006
CRP
3-50 mg/L 2.28 (1.18-4.42) .01
>50 mg/L 2.69 (1.29-5.60) .008
White cell count>12,000/mm3 2.28 (1.22-4.25) .009
CI, Confidence interval; CRP, C-reactive protein.
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emphasized that these survival data have been obtained in
patients participating in clinical trials (ie, sufficiently fit to
undergo chemotherapy  extensive surgery), and thus are
more likely to experience a longer survival than a nonselected
population of MPM patients.
The outcome of unselected patients with MPM has
been evaluated less extensively; therefore, prognostic fac-
tors are less known in these patients. In a Mayo Clinic
report,12 all patients referred for MPM were analyzed.
Three-year survival rates were 6%, 3.7%, and 15% after
biopsy, pleurectomy, or extrapleural pneumonectomy, re-
spectively.12 Long-term survivors were observed only
among patients treated by extrapleural pneumonectomy,
with a 5-year survival rate of 15%.12 However, this wasThe Journal of Thoracic and Cara retrospective study and it is likely that long-term survi-
vors were those individuals more fit and/or with less
extensive disease.
In our study, we did not include patients treated by
extrapleural pneumonectomy because of the substantial
differences between these patients and the whole popula-
tion of patients with MPM. Among our consecutive pa-
tients seen at the time of diagnosis, median survival
was 12 months. Two-, 5-, and 7-year overall survival
was 26%, 11%, and 5%, respectively, showing that
long-term survival is not exceptional, even in these pa-
tients who were not treated with extensive surgery. Factors
associated with long-term survival at univariate analysis
were asbestos exposure, age, American Society of Anes-
thesiologists class, histology (nonepithelioid type), abnor-
mal CRP levels, and increased white cell count.
With respect to CRP, abnormal values (>3mg/L), indicat-
ing some degree of systemic inflammation, were present in
approximately 82% of our patients with MPM, whereas ap-
proximately one-third (32%) had levels>50 mg/L. A level-
dependent relationship with survival was observed, with an
adjusted hazard ratio of 2.28 (95% CI, 1.18-4.42) for CRP
equal to 3-50 mg/L compared with CRP< 3 mg/L, and
an adjusted hazard ratio of 2.69 (95% CI, 1.29-5.60) for
CRP>50 mg/L compared to CRP<3 mg/L. Multivariate
analysis showed that nonepithelioid histology, age, CRP
levels, and leukocytosis were predictors of survival. Thus,diovascular Surgery c Volume 145, Number 5 1309
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Ssystemic inflammation seems to be an independent predictor
of poor outcome in nonsurgically treated patients with
MPM. Proinflammatory cytokines and associated growth
factors are involved in carcinogenesis through their effects
on tumor cell growth, survival, proliferation, and migra-
tion.20 In addition, tumor cells themselves release proin-
flammatory cytokines.20 Serum CRP, a well-known and
routinely measured marker of inflammation, is produced
in the liver in response to high levels of proinflammatory
cytokines, particularly interleukin (IL)-1, tumor necrosis
factor-a, and IL-6.21 C-reactive protein has been identified
as a prognostic factor in several tumors; with respect to in-
trathoracic malignancies, its relationship with prognosis
has been suggested in advanced nonsmall cell lung cancer.22
Based on 2 different French cohorts, we have reported pre-
viously that CRP level is also an independent predictor of
survival in resectable stage I to II nonsmall cell lung can-
cer.23 Several mechanisms could explain the prognostic
value of CRP. This protein could be amarker of IL-6 produc-
tion by the tumor, thereby reflecting the tumor burden.21-23
Furthermore, CRP is known to block p53-induced apopto-
sis,24 and increased CRP levels could be an indirect marker
of the tumor ability to maintain a protumor immune
microenvironment.24
Comparison of our results with the available literature is
difficult because only a few studies assessed the prognostic
value of CRP in this setting. In particular, neither the Euro-
pean Organization for Research and Treatment of Cancer25
nor the Cancer and Leukemia Group B studies26 (based on
204 and 337 patients, respectively), assessed the prognostic
role of CRP levels. Recently, Tanrikulu and colleagues27 re-
ported that a CRP level>50 mg/L was an independent pre-
dictor of survival in MPM patients; however, they did not
investigate whether this relationship with survival was level
dependent. Similarly, Kao and associates,28 in a phase II
study comparing thalidomide alone with thalidomide asso-
ciated with cisplatin–gemcitabine in MPM found that in-
creases in vascular endothelial growth factor and CRP at
baseline were predictors of poor outcome in both treatment
arms.
Identification of patients with poor prognosis could be
useful for individual tailoring of treatment strategies.
C-reactive protein measurement, together with other avail-
able clinicopathologic parameters, could help in identify-
ing patients who require a more aggressive treatment or,
on the contrary, could help in avoiding aggressive multi-
disciplinary management in severely ill patients that
showing several negative prognostic factors. These remain
to be demonstrated formally in adequately designed
studies.
In conclusion, survival of patients with MPM remains
poor. Chemotherapy and multimodal treatment strategies
also involving curative surgery could improve survival in
some patients. Knowledge of prognostic factors, including1310 The Journal of Thoracic and Cardiovascular SurCRP levels, could help in tailoring treatment options to
each individual patient.References
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